28 June 2018 - Roche’s Alecensa has won NICE backing as a treatment for a rare type of lung cancer, over-turning a prior decision to reject NHS funding for the drug.

In draft guidelines, the Institute is now endorsing the drug, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase positive advanced non-small cell lung cancer, which affects around 925 people in England.

The recommendation comes as a result of an ongoing clinical trial that has shown Alecensa (alectinib) is more effective in delaying disease progression, by around 15 months more, than the current standard of care, crizotinib, NICE said.

Read Pharma Times article